Kyntra Bio
KYNB
112 hedge funds and large institutions have $146M invested in Kyntra Bio in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 42 reducing their positions, and 14 closing their positions.
543% more call options, than puts
Call options by funds: $4.07M | Put options by funds: $633K
134% more capital invested
Capital invested by funds: $62.1M → $146M (+$83.4M)
86% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 14
12% more funds holding
Funds holding: 100 → 112 (+12)
0.37% less ownership
Funds ownership: 2.85% → 2.48% (-0.37%)
38% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$1.98M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.86M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$620K |
| 4 |
State Street
Boston,
Massachusetts
|
+$607K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$376K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.15M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.1M |
| 3 |
D.E. Shaw & Co
New York
|
-$3.06M |
| 4 |
Two Sigma Investments
New York
|
-$2.22M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.06M |
KYNB Hedge Fund Activity: Q1 2024 in Review
112 of the 6,957 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2024, worth a combined $146M — up 134% from $62.1M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new KYNB positions and 14 closed out — a net gain of 12 holders — while 26 added to existing stakes and 42 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $1.98M. The largest seller was Armistice Capital, cutting an estimated $3.15M.
- 112 institutional investors held Kyntra Bio (KYNB) as of Q1 2024, up from 100 in Q4 2023.
- Funds reported $146M of Kyntra Bio stock for Q1 2024, up 134% quarter-over-quarter.
- 26 funds opened new Kyntra Bio positions in Q1 2024 and 14 closed out, a net change of +12 holders.
- The largest Kyntra Bio buyer in Q1 2024 was 683 Capital Management, an estimated $1.98M added.
- The largest Kyntra Bio seller in Q1 2024 was Armistice Capital, an estimated $3.15M sold.
Based on aggregated 13F filings for Q1 2024.